伊布替尼
威尼斯人
套细胞淋巴瘤
医学
淋巴瘤
布鲁顿酪氨酸激酶
癌症研究
肿瘤科
内科学
白血病
慢性淋巴细胞白血病
受体
酪氨酸激酶
作者
Constantine S. Tam,Mary Ann Anderson,Christiane Pott,Rishu Agarwal,Sasanka M. Handunnetti,Rodney J. Hicks,Kate Burbury,Gillian Turner,Juliana Di Iulio,Mathias Bressel,David Westerman,Stephen Lade,Martin Dreyling,Sarah‐Jane Dawson,Mark A. Dawson,John F. Seymour,Andrew W. Roberts
标识
DOI：10.1056/nejmoa1715519
摘要
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination.
科研通智能强力驱动
Strongly Powered by AbleSci AI
薰硝壤
不配.
Singularity
Henry
浅尝离白
8R60d8
juziyaya
个性的紫菜
shinysparrow
iNk
有人
咖啡豆
寻道图强
Leonardi
竹筏过海
pcr163
肯德鸭
itsserene
毛豆爸爸
xjcy
皖公网安备34019202002308
